|
Oculus Innovative Sciences is a biopharmaceutical company that
develops, manufactures and markets a family of products based upon the
Microcyn® Technology platform, which is intended to help prevent and
treat infections in chronic and acute wounds. The Microcyn Technology
platform is a shelf-stable biocompatible solution containing active oxychlorine compounds.
The solutions derived from the Microcyn Technology platform have
demonstrated, in a variety of research and investigational studies,
the ability to treat a wide range of pathogens, including
antibiotic-resistant strains of bacteria (including MRSA and VRE),
viruses, fungi and spores. The technology has also demonstrated wound
healing in chronic and acute wounds in clinical investigational
studies. It has been commercialized outside of the United States for the treatment of infected wounds.
Oculus' principal operations are in Petaluma, California, and it
conducts operations in Europe, Latin America and Japan through its
wholly owned subsidiaries, Oculus Innovative Sciences Netherlands
B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan
K.K. Oculus' website is www.oculusis.com.
|